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Deficient clearance of apoptotic cells reportedly contributes to the etiopathogenesis of 
the autoimmune disease systemic lupus erythematosus (SLE). Based on this knowledge, 
we developed a highly specific and sensitive test for the detection of SLE autoantibodies 
(AAb) utilizing secondary NEcrotic cell (SNEC)-derived material as a substrate. The goal 
of the present study was to validate the use of SNEC as an appropriate antigen for the 
diagnosis of SLE in large cohort of patients. We confirmed the presence of apoptotically 
modified autoantigens on SNEC (dsDNA, high mobility group box 1 protein, apoptosis- 
associated chromatin modifications, e.g., histones H3-K27-me3; H2A/H4 AcK8,12,16; 
and H2B-AcK12). Anti-SNEC AAb were measured in the serum of 155 patients with SLE, 
89 normal healthy donors (NHD), and 169 patients with other autoimmune connective 
tissue diseases employing SNEC-based indirect enzyme-linked immunosorbent assay 
(SNEC ELISA). We compared the test performance of SNEC ELISA with the routine 
diagnostic tests dsDNA Farr radioimmunoassay (RIA) and nucleosome-based ELISA 
(anti-dsDNA-NcX-ELISA). SNEC ELISA distinguished patients with SLE with a specificity 
of 98.9% and a sensitivity of 70.6% from NHD clearly surpassing RIA and anti-dsD-
NA-NcX-ELISA. In contrast to the other tests, SNEC ELISA significantly discriminated 
patients with SLE from patients with rheumatoid arthritis, primary anti-phospholipid syn-
drome, spondyloarthropathy, psoriatic arthritis, and systemic sclerosis. A positive test 
result in SNEC ELISA significantly correlated with serological variables and reflected the 
uptake of opsonized SNEC by neutrophils. This stresses the relevance of SNECs in the 
pathogenesis of SLE. We conclude that SNEC ELISA allows for the sensitive detection of 
pathologically relevant AAb, enabling its diagnostic usage. A positive SNEC test reflects 
the opsonization of cell remnants by AAb, the neutrophil recruitment to tissues, and the 
enhancement of local and systemic inflammatory responses.
Keywords: systemic lupus erythematosus, secondary necrosis, autoimmunity, autoantibodies, inflammation, 
connective tissue diseases
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inTrODUcTiOn
Systemic lupus erythematosus (SLE) is a chronic inflammatory 
autoimmune disease. Its pathogenesis is multifactorial including 
the involvement of genetic (1), hormonal (2), immunologic (3), 
and environmental factors like infections (4, 5). The appearance of 
autoantibodies (AAb) is the hallmark of systemic autoimmunity 
in SLE and results from a series of immune-mediated events that 
typically precede the onset of clinical symptoms by several years. 
The development of autoimmunity is considered to be partly 
triggered by impaired clearance of apoptotic cells in the germinal 
centers of the lymph nodes (6–9). Apoptotic cells that are not 
cleared rapidly by professional phagocytes lose their membrane 
integrity and, consequently, release cytoplasmic and nuclear 
autoantigens. These antigens are usually connected to damage-
associated molecular patterns (DAMPs) like the high mobility 
group box 1 protein (HMGB1) (10). The material generated in the 
absence of a proper clearance is designated as secondary NEcrotic 
cells (SNECs) (11–13). The concomitant release of DAMPs and 
nucleic acids triggers an inflammatory response (14, 15) which, 
in combination with the accessibility of autoantigens, precipitates 
the production of SNEC-specific AAb (16). After autoimmun-
ity is established uncleared post-apoptotic material serves as 
autoantigen repository for the formation of pathogenic immune 
complexes (ICs) (17, 18). These complexes form in situ or deposit 
in various tissues, especially in the kidney, skin, and joints, where 
they trigger inflammation and tissue damage (19, 20).
In 1948, Hargraves discovered the LE cell as first test for 
diagnosing SLE [reviewed in Ref. (21)] representing a phago-
cytic cell that has ingested the secondary necrotic nucleus of 
another cell closely resembling SNEC (22). AAb against nuclear 
proteins are essential to form LE cells (23, 24) suggesting recog-
nition of SNEC in the context of autoimmunity in SLE (25, 26). 
Accordingly, LE cells reportedly indicate serologically and clini-
cally active disease with major organ involvement. After several 
decades, the LE cell test was replaced by serum autoantibody 
testing in 1997, not least because LE cell testing is time consum-
ing and challenging (27,  28). The presence of AAb increases 
the risk for clinical disease by at least 40-fold (29). A plethora 
of autoantibody specificities can be detected in patients with 
SLE that comprise reactivities against dsDNA, nucleosomes, 
RNA-protein complexes, Smith antigen (Sm), and ribosomal 
proteins (30).
Considering the aforementioned pathophysiologic events, we 
hypothesized that the detection of anti-SNEC AAb is a highly 
specific and potentially sensitive tool for the classification of SLE. 
Thus, the goal of the present study was to validate the use of SNEC 
as an appropriate antigen for the diagnosis of SLE in large cohort of 
patients. Employing SNEC as antigen, we developed a specific and 
sensitive high-throughput test to identify patients with pathogenic 
AAb against post-apoptotic cells. This anti-SNEC enzyme-linked 
immunosorbent assay (ELISA) discriminated SLE patients from 
healthy individuals and patients with other autoimmune connec-
tive tissue diseases with a specificity and sensitivity of 98.9 and 
70.6%, respectively, surpassing currently used standard detection 
methods.
MaTerials anD MeThODs
Patient and normal healthy Donor  
(nhD) serum samples
This study was carried out in accordance with the recommenda-
tions of institutional guidelines and the approval of the ethical 
committee of the Universitätsklinikum Erlangen (permit # 54_14B). 
The protocol was approved by the ethical committee of the Univer-
sitätsklinikum Erlangen (permit # 54_14B). Written informed 
consent was given by each donor in accordance with the Declara-
tion of Helsinki. Serum samples from NHD and patients with 
SLE, RA, SpA, PsA, and SSc, fulfilling the 1997 American College 
of Rheumatology criteria, were obtained at the Department of 
Rheumatology and Immunology of the Universitätsklinikum 
Erlangen. Sera from patients with primary anti-phospholipid syn-
drome (PAPS) were obtained from the Department Rheumatology 
and Clinical Immunology of the Spedali Civili and University of 
Brescia. Samples were stored at −20°C until analysis.
Preparation of snecs
Peripheral blood mononuclear cells (PMBC) were obtained from 
heparinized whole NHD blood and isolated by density gradient-
based isolation using Lymphoflot (Bio-Rad, Dreieich, Germany) 
as previously described (31). Isolated PBMCs were adjusted to 
a concentration of 5 × 106 cells/ml in PBS and irradiated using 
240  mJ/cm2 UVB light for 90  s. After incubation for 24  h at 
37°C and antigen retrieval at 56°C, SNEC was stored at −20°C 
containing 5 mM EDTA. Before coating, SNEC was washed in 
10 mM Tris buffer containing 1 mM EDTA (pH 8.0). For ex vivo 
phagocytosis assays, SNEC was concentrated to 15 × 107 cells/ml 
and labeled with propidium iodide (PI).
Ex Vivo Phagocytosis assays
Fresh heparinized whole blood from NHD was added to polysty-
rene tubes and 12% serum of NHD or patients with SLE and 10% 
PI-stained SNEC (15 × 107/ml) was added. Samples were incubated 
for 4 h at 37°C to allow uptake of SNEC by phagocytes and stained 
for HLA-DR (FITC), CD16 (APC), and DNA (Hoechst33342) for 
30 min at 4°C in the dark. After hypotonic lysis of erythrocytes 
and fixation of the cells, samples were measured by flow cytom-
etry (Gallios™ Beckman Colter, Krefeld, Germany) and analyzed 
using Kaluza 1.5 software (Beckmann Colter). Uptake of SNEC is 
presented as phagocytosis index calculated using the percentage of 
PI-positive cells and the mean fluorescent intensity.
snec elisa
The serum of NHD and patients affected by several pathological 
conditions was analyzed by ELISA for the presence of anti-SNEC 
IgG AAb. 96-well microtiter plates (Nunc-Immuno™Maxisorp) 
were coated overnight at 4°C with 50 µl of Poly-l-Lysine (20 µg/ml) 
in 10 mM Tris buffer containing 1 mM EDTA (pH 8.0). Plates 
were washed three times with 200 µl of washing buffer [phos-
phate-buffered saline (PBS), 0.05% Tween 20, pH 7.4] after each 
incubation step. After coating overnight at 4°C with SNEC in 
10 mM Tris buffer containing 1 mM EDTA (pH 8.0), plates were 
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blocked for 1 h at room temperature (RT) with 100 µl blocking 
agent (2% BSA in PBS) per well, 50 µl of serum per well (1:200 
in PBS-T) was added and incubated for 1 h at RT. Next, 50 µl 
of goat anti-human IgG Fc HRP-conjugated (Southern Biotech, 
Birmingham, AL, USA) antibody (1:50,000 in washing buffer) 
was added and incubated for 1 h at RT. Finally, plates were incu-
bated with 50 µl of substrate solution [substrate buffer (0.1 M 
Na2HPO4, 0.05  M citrate acid, pH 5.0), 10% TMB, and 0.02% 
H2O2 (30%)] for 5 to 10 min. The reaction was stopped with 50 µl 
of H2SO4 (25%) and absorbances were read at 450 and 620 nm 
reference wavelength. To account for differences between plates, 
values were corrected using a standard serum applied on each 
plate.
characterization of snec autoantigens  
by elisa
ELISA was performed as described above. Antibodies detecting sev-
eral autoantigens [mAb #34: mouse anti-histone H3 (32); mAb #42: 
mouse anti-DNA; mAb BT131: mouse anti-apoptotic nucleosome 
(33); mAb BT164: mouse anti-H3-K27me3 (34); mAb KM-2: mouse 
anti-H4-AcK8,12,16 (35); mAb LG11-2: mouse anti-H2B-AcK12 
(36); rabbit anti-HMGB1 (Abcam, Cambridge, UK)] were added 
at the indicated concentrations in PBS-T (containing 1% BSA) and 
incubated for 1 h at RT. The respective secondary antibodies, goat 
anti-mouse IgG Fc HRP-conjugated (Jackson ImmunoResearch, 
Suffolk, UK), goat anti-rabbit IgG Fc HRP-conjugated (Southern 
Biotech, Birmingham, AL, USA), and goat anti-human IgG Fc 
HRP-conjugated (Southern Biotech, Birmingham, AL, USA) were 
added (1:10,000 in PBS-T, 1% BSA) for 1 h at RT.
immunofluorescence staining
Eight-well Nunc chamber slides (VWR, Darmstadt, Germany) 
were coated, washed, and blocked as described above. Wells 
were incubated with the serum of one NHD with a low SNEC 
ELISA value and the serum of one SLE patient with a high SNEC 
ELISA value (1:200 in PBS-T) or antibodies detecting histone H3 
(mAb #34) and mouse anti-H3-K27me3 (mAb BT164). Goat anti-
human IgG FITC (Jackson ImmunoResearch, Suffolk, UK), goat 
anti-mouse IgG Cy®5 (Jackson ImmunoResearch, Suffolk, UK), 
and goat anti-rabbit IgG Cy®5 (Jackson ImmunoResearch, Suffolk, 
UK) were added and incubated for 1  h in the dark. A control 
staining lacking a primary antibody was included. Finally, slides 
were washed with PBS and H2O, embedded in DAKO fluorescent 
mounting medium (Agilent Technologies, Santa Clara, CA, USA) 
and analyzed using the Eclipse Ni-U (Nikon Corporation, Tokyo, 
Japan).
live Fluorescence Microscopy
Fresh heparinized whole blood from NHD was obtained and 
12% serum of patients with SLE and 10% PI-stained SNEC 
(150 × 106 cells/ml) were added. The samples were incubated for 
1 h at 37°C. After hypotonic lysis of erythrocytes and fixation 
with 4% PFA, cells were deposited on chamber slides. Slides were 
blocked with 10% FCS and stained for CD15 (APC) and DNA 
(Hoechst33342) and the respective isotype control antibody for 
2 h at RT in the dark and analyzed using the Eclipse Ni-U.
adsorption of anti-snec aab  
From sle serum
Serum C-reactive protein (CRP) was purified using immobilized 
p-Aminophenyl Phosphoryl Choline agarose gel (Thermofisher) 
as per the manufacturer’s instructions. CRP bound to agarose was 
incubated with SNEC for 1 h at RT (13). Anti-SNEC AAb were 
removed from SLE serum by incubation with SNEC-bound CRP 
agarose by incubation for 1 h at RT.
statistical Data analysis
Age, sex, comorbidities, organ involvement, and disease onset were 
recorded for all patients. CRP levels, erythrocyte sedimentation 
rate (ESR), rheumatoid factor (RF), dsDNA radioimmunoassay 
(RIA), anti-dsDNA-NcX-ELISA, extractable nuclear antigen 
(ENA) profiles, and complement levels (C3 and C4) were meas-
ured on the same day of serum collection. Disease activity score 
European Consensus Lupus Activity Measurement Manifestation 
(ECLAM) was calculated. For comparisons between two groups, 
Mann–Whitney U-tests for numerical variables and exact 
χ2-tests for nominal characteristics were employed. ANOVA with 
Bonferroni Post Hoc correction was employed for comparisons 
among several groups. Associations among clinical and labora-
tory variables were measured by Bravais-Pearson correlation 
coefficients and corrected after Bonferroni. The discriminatory 
power of a test was evaluating calculating the receiver operating 
characteristic (ROC) method. Cumulative predicted probabilities 
[the area under the curve, positive predictive value (PPV), nega-
tive predictive value (NPV), diagnostic odds ratio (DOR), cutoff, 
sensitivity, specificity] were calculated for numeric comparison of 
ROC curves. All statistical analyzes were performed using IBM 
SPSS Software (version 21) and GraphPad Prism 5.03 software. 
A p value ≤0.05 was considered statistically significant.
resUlTs
aab From Patients With sle recognize 
snec-Borne autoantigens Modified 
During apoptosis
We employed SNEC as immobilized antigen in an indirect ELISA 
(Figure S1A in Supplementary Material) to detect SLE-specific 
antibodies. We demonstrated the availability of specific apoptoti-
cally modified nuclear autoantigens on SNEC (Figure 1A) and 
confirmed the presence of DNA, histone H3, nucleosomes, and 
histones carrying several apoptotic modifications (histone H3 
K27-me3; histone H2A/H4 AcK8,12,16, histone H2B-AcK12). 
Representative pictures of repeated SNEC antigen characteriza-
tion are shown. Analyzes by immunofluorescence revealed that 
autoreactive IgG present in the sera of patients with SLE strongly 
bound to immobilized SNEC, whereas sera of NHD lacked 
reactivity (Figure  1B). SNEC was recognized by DNA- and 
nucleosome-specific AAb in a particular manner (Figure  1C) 
resembling the recognition pattern of SLE serum-derived AAb 
(Figure 1C). These monoclonal antibodies also recognized anti-
gens on HEp-2 cells; however, apoptotically modified histone H3 
was recognized to a lesser extent (Figure 1D). HMGB1 was also 
found on immobilized SNEC linked to apoptotic DNA (Figure S1B 
FigUre 1 | Immobilized secondary NEcrotic cells (SNECs) expose naïve and modified nuclear autoantigens. (a) Recognition of immobilized autoantigens  
on SNEC by specific antibodies. Coated material contained histone H3 (#34), DNA (#42), nucleosomes (BT131), and the apoptotically modified histones  
H3 K27-me3 (BT164), H2A/H4 AcK8,12,16, (KM-2), and H2B-AcK15 (LG11-2). Respective isotype control antibodies (iso) displayed background signals.  
(B) Immunofluorescence of SLE-borne IgG autoantibodies (AAb) binding immobilized SNEC counter-stained for DNA by propidium iodide (PI). NHD, normal  
healthy donor; SLE, systemic lupus erythematosus; magnification 20×. (c) Immunofluorescence of histone H3 and modified histone H3 K27-me3 on immobilized 
SNEC counter-stained for DNA by PI; magnification 40×. (D) Immunofluorescence staining of histone H3 and modified histone H3 K27-me3 on HEp-2 cells.  
(e) Immunofluorescence of binding pattern of IgG autoantibodies present in the serum of patients with SLE to immobilized SNEC stained for DNA by PI; FOV,  
field of view. (F) Morphometric evaluation of (e), intensity of DNA staining versus the intensity of IgG staining.
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TaBle 1 | Demographical and serological characteristics of the study cohorts.
nhD sle PaPs ra spa Psa ssc
n 89 155 37 53 20 30 29
Sex (Female/male) 52/33 133/22 28/9 40/13 7/13 14/16 19/9
Current age (years) Median/IQR 27.5/25–33 44.5/22–42 47/37–40 62.8/53–71 46.2/36–57 54.1/46–63 55.3/50–72
Age at diagnosis (years) Median/IQR na 29.2/10–76 na 45.3/36–57 31.6/18.5–41.6 40.2/33–53 47.9/42–62
CRP (mg/dl) [<5 mg/L] Median/IQR na 3.7/2.2–6.2 na 3.5/2.3–8.3 4.9/2.55–9.5 5.0/2.1–7.0 6.3/2.8–9.4
RF (IE/ml) [0–20 IE/ml] Median/IQR na na na 25.5/0–183 na na na
ACPA (U/ml) [<10 U/ml] Median/IQR na na na 57.5/3.6–294.3 na na na
a-SNEC IgG (mOD)  
[<246 mOD]
Median/IQR 85.0/64.0–121.5 309.8/239.4–375.3 61.0/12.4–94.0 85.9/42.0–148.8 50.6/38.5–86.4 52.0/34.6–92.9 109.0/89.9–122.1
SNEC ELISA positivity % 1.1 70.6 0.0 1.9 0.0 0.0 3.4
ACPA, anti-citrullinated peptide antibody; a-SNEC IgG, anti-secondary necrotic cell-IgG antibody; CRP, C-reactive Protein; IE, Internationale Einheit (engl. International units); IQR, 
interquartile range; mOD, mean optical density; na, not available; PAPS, primary anti-phospholipid syndrome; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; 
SLE, systemic lupus erythematosus; SpA, spondyloarthropathy; SSc, systemic sclerosis; U, unit; NHD, normal healthy donor.
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in Supplementary Material). Murine AAb bound SNEC in a 
unique pattern preferentially targeting cells with low DNA densi-
ties (Figure 1C). Morphometry confirmed that human SLE AAb 
showed a similar binding pattern preferring cells with fringed 
nuclei and decondensed chromatin when compared to targets 
with bright round nuclei (Figures 1E,F).
The Test Performance of snec elisa 
surpasses That of current routine assays
To establish a reproducible assay, we tested the linearity of SNEC 
ELISA employing serial dilutions of positive and negative sera 
(Figure S1C in Supplementary Material). For further analyzes, we 
used a serum dilution factor of 200 lying in the linear detection 
range. Comparison of different apoptosis stimuli resulted in com-
parable autoantibody detection for UVB- or Dexamethasone-
induced apoptosis (Figure S1D in Supplementary Material). To 
assess the performance of SNEC ELISA, we studied 155 patients 
with SLE [median age 44.5  years (inter quartile range (IQR) 
22–42)] and 89 normal healthy donors (NHD) [median age 
27.5 years (IQR 25–33)] (Table 1). A summary of demographical, 
serological, and clinical data of all study cohorts is presented in 
Tables 1 and 2. The reproducibility of SNEC ELISA in terms of 
batch variability was tested and corrected using a standard serum, 
which revealed reproducible signals.
Secondary NEcrotic cell ELISA values from individuals of the 
NHD and SLE cohorts were not dependent on age (Figures S1F,G 
in Supplementary Material). ROC analyzes using the NHD sera 
as control cohort determined positive sera above the cutoff of 
246 mOD (Figure 2A). 70.6% of patients with SLE showed sero-
positivity in SNEC ELISA, whereas just 1.1% of NHD were positive 
(Figure 2A). Patients with secondary anti-phospholipid syndrome 
(sAPS, 72.7%) are depicted additionally in a separate cohort and 
are undistinguishable from the patients with SLE without sAPS 
(Figure  2A). We employed sera from patients with other con-
nective tissue disorders, namely PAPS (0%), rheumatoid arthritis 
(RA, 1.9%), spondyloarthropathy (SpA, 0%), psoriatic arthritis 
(PsA, 0%), or systemic sclerosis (SSc, 3.4%) (Figure 2A) showing 
cumulatively only 1.2% seropositivity in SNEC ELISA (Figure 2A).
Receiver operating characteristic analysis showed a specificity 
of 98.9% at a sensitivity of 70.6% for SNEC ELISA (Figure 2B) 
surpassing current routine assays like the anti-dsDNA-NcX-
ELISA (EUROIMMUN) and the Farr radioimmunoassay (IBL 
International) in our cohort (Figure 2B). Analysis of the ROC 
curves of combined results of RIA and ENA nucleosome or 
ENA histone revealed that the sensitivity of SNEC ELISA also 
outperformed the combination of these tests (Figure S1E and 
Table S1 in Supplementary Material). A PPV of 99.1% for SNEC 
ELISA confirmed the high accuracy of the assay (Figure  2B), 
comparable to RIA and anti-dsDNA-NcX-ELISA (98.3 and 98.5%, 
respectively). The NPV, indicating the percentage of true negative 
test results, was 66.2% for SLE, clearly exceeding RIA and anti-
dsDNA-NcX-ELISA (NPV: 30.1 and 41.2%). SNEC ELISA was 
the most effective test with a DOR of 211.2, performing better 
than RIA (DOR 25.0) and anti-dsDNA-NcX-ELISA (DOR 46.3) 
(Figure 2B).
The most frequently affected organs in our study cohort were 
joints (62.1%), skin (60.1%), and kidneys (40.5%) (Table  3), a 
distribution similar to previous reports. None of the employed 
diagnostic tests [anti-nuclear antigen (ANA), anti-dsDNA-NcX-
ELISA, RIA, and SNEC ELISA] predicted enhanced risks for 
any organ involvement (Figure  2C). Interestingly, the number 
of patients with photosensitivity or SLE-related central nervous 
system involvement was significantly lower if SNEC ELISA was 
positive (Figure  2C, red). Correlation analyzes demonstrated 
further associations of anti-SNEC antibodies with serological 
variables of SLE (Figure 3; Tables S2 and S3 in Supplementary 
Material).
anti-snec antibodies correlate With 
serological Variables of sle
In order to explore the degree of association between SNEC 
ELISA, anti-dsDNA-NcX-ELISA, RIA, and serological variables 
commonly used for monitoring SLE disease activity, we analyzed 
complement levels (C3 and C4), markers of inflammation (CRP 
and ESR), and levels of AAb (ANA and ENA profiles) (Figure 3; 
Tables S2 and S3 in Supplementary Material). One-way ANOVA 
analyzes revealed that the levels of anti-SNEC and anti-dsDNA-
NcX antibodies significantly correlated with increasing titers of 
ANA on HEp-2 (p =  0.1 ×  10−26 and 0.4 ×  10−8, respectively) 
(Table S2 in Supplementary Material). Bonferroni post hoc testing 
TaBle 2 | Serological and clinical characteristics of the SLE cohort.
Variable n Mean ± sD Frequency 
altered (%)
Serology ANA on HEp-2 (1/) [≥1/320] 152 1544.2 ± 3389.3 71.2
Radioimmunoassay (RIA) 
dsDNA (U/ml) [0–7 U/ml]
153 22.3 ± 79.2 39
C3 (mg/dl) [81.1–157 mg/dl] 153 87.6 ± 21.3 63
C4 (mg/dl) [12.9–39.2 mg/dl] 153 15.4 ± 5.7 14
CRP (mg/l) [<5 mg/L] 152 5.4 ± 6.20 17
Anti-CL IgG [0–14 GPL U/ml] 56 28.0 ± 56.2 37.5
Anti-β2GP IgG [0–10 U/ml] 56 12.3 ± 25.3 21.4
ESR (mm/60min) [<20 F; <15 
M mm/60 min]
146 18.7 ± 13.5 42
a-SNEC IgG [mean optical 
density (mOD)] [<246 mOD]
153 264.5 ± 100.6 71
Ncx dsDNA ELISA (IE/ml)  
[<100 IE/ml]
153 146.9 ± 187.6 43
ENA [0–3] Histones 155 0.72 ± 1.05 41
Nucleosomes 155 0.74 ± 1.06 44
Ro-52 (52 kDa) 155 0.85 ± 1.29 36
SS-A (60 kDa) 155 0.99 ± 1.34 39
RNP/Sm 155 0.71 ± 1.21 31
AMA-M2 155 0.15 ± 0.54 11
Ribosomal P protein 155 0.21 ± 0.57 17
PCNA 155 0.05 ± 0.20 6
Centromer B 155 0.04 ± 0.24 4
Jo-1 155 0.03 ± 0.20 3
PM-Scl 155 0.08 ± 0.26 13
Scl-70 155 0.07 ± 0.36 5
SS-B 155 0.25 ± 0.78 12
RNP C 155 0.09 ± 0.37 9
RNP A 155 0.31 ± 0.83 15
RNP 70 155 0.25 ± 0.73 12
Sm 155 0.20 ± 0.64 12
Clinic SLEDAI (0–105) 84 2.82 ± 2.65
ECLAM (1–10) 153 5.73 ± 2.51
C3/C4; complement factor 3/4; Anti-β2GP1 IgG, anti-β2 glycoprotein1 IgG; anti-CL, 
anti-cardiolipin IgG; ANA, anti-nuclear antigen; ENA, extractable nuclear antigen; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; ECLAM, European Consensus 
Lupus Activity Measurement Manifestation; SLEDAI, SLE disease activity index.
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confirmed significantly increased values of anti-SNEC antibodies 
for ANA titers above 1:1,000 (Figure 3A). The levels of anti-dsDNA 
antibodies detected by RIA did not increase proportionally with 
ANA titers (Table S2 in Supplementary Material). We found a sig-
nificant negative correlation between complement C3 levels and 
all anti-nuclear antibody tests (RIA Person’s r = −0.223, p = 0.006; 
SNEC r = −0.259, p = 0.001; dsDNA-NcX r = −0.238, p = 0.003) 
(Table S2 in Supplementary Material). While CRP levels did not 
correlate with any of the tests, C4 negatively correlated with RIA 
and ESR with SNEC ELISA and anti-dsDNA-NcX ELISA (Table S3 
in Supplementary Material). The anti-SNEC antibody levels cor-
related with 2 out of the 17 markers of the ENA profile: histone 
and nucleosome, both considered specific for SLE (Figure 3B). 
Taken together, anti-SNEC autoantibody levels significantly cor-
related with the most important canonical serological variables. 
The anti-SNEC antibody levels and the RIA assay were independ-
ent of SLE disease activity (Figure 3D; Table S3 in Supplementary 
Material). Approximately 50% of the patients tested showed low 
ECLAM values between 4 and 7 most likely due to permanent 
therapeutic treatment (Figure S1H in Supplementary Material).
Phagocytosis of snec by neutrophils  
is Mediated by snec-specific aab
We investigated the uptake of SNEC opsonized by anti-SNEC 
AAb (SNEC immune complexes: SNEC-IC) in a whole blood 
phagocytosis assay. We observed a positive correlation of uptake 
of fluorescent SNEC into neutrophils (CD16POS-HLA-DRNEG) in 
the presence of sera from SLE patients measured by flow cytometry 
(Spearman’s r = 0.5103; p < 0.0001) (Figure 4A). Consistent with 
published data, NHD with low levels of autoreactive IgG showed 
very low uptake of SNEC into neutrophils (Figure 4A). Z-stack 
series of immunofluorescence images confirmed the uptake of 
SNEC into CD15POS neutrophils in the presence of a high anti-
SNEC IgG SLE serum (Figure 4B). SNEC was only sporadically 
present in neutrophils when NHD serum was employed. Uptake 
of SNEC was also visible in CD15NEG monocytes in the presence 
of both SLE and NHD sera (Figure  4B, red arrow). CD16POS-
HLA-DRNEG neutrophils displayed a substantially diminished 
uptake of SNEC when anti-SNEC antibodies were adsorbed 
from SLE serum (SNEC, adsorbed) suggesting that the uptake 
of SNEC by neutrophils is mainly mediated by opsonizing AAb 
(Figure 4C). We confirmed this result for 12 different SLE sera 
(Figure  4D). Despite achieving moderate (3–48%) anti-SNEC 
autoantibody adsorption, SNEC phagocytosis was reduced up to 
85% (Figure 4E). This suggests that SNEC preferentially catches 
the high-affine pathologically relevant AAb from sera of patients 
with SLE.
DiscUssiOn
Patients with SLE are classified based on a combination of clinical 
and laboratory findings. Importantly, the sole presence of biopsy-
proven lupus nephritis together with positivity for ANA or anti-
dsDNA antibodies is declared as sufficient for a definite diagnosis 
(37) emphasizing the pivotal role of circulating pathogenic AAb 
for classification of SLE. However, current tests employing nuclear 
material derived from cell lysates or recombinant proteins for the 
detection of SLE-specific AAb disregard the apoptotic nature 
of these antigens. This is particularly critical since a clearance 
deficiency of apoptotic cells contributes to the etiopathogenesis 
of SLE (6, 38).
Considering the pathophysiological events in SLE, we devel-
oped a high-throughput assay employing SNEC as target for 
autoreactive IgG. The major goal of our study was to establish a 
reproducible substrate for the sensitive detection of SLE-typical 
AAb. The selection of PBMCs for the production of SNEC was 
based on the fact that the accumulation of apoptotic material in 
germinal centers is the main driving force leading to the break of 
self-tolerance. Since lymphocytes have the capacity to proliferate 
and die by canonical apoptosis, we supposed that these cells are 
likely to mainly expose pathogenically relevant autoantigens in 
the context of SLE.
Our test distinguished patients with SLE from NHD with high 
specificity and sensitivity of 98.9 and 70.6%, respectively. In the 
same study cohort, anti-dsDNA-NcX-ELISA, and RIA, commonly 
used for routine testing, showed sensitivities of 43.1 or 37.9%, 
respectively. Although, RIA is considered the gold standard for 
FigUre 2 | SLE-derived AAb are specifically and sensitively detected by secondary NEcrotic cell (SNEC) ELISA. (a) Reactivity of sera from normal healthy  
donors (NHD) and patients with SLE, secondary anti-phospholipid syndrome (sAPS, gray dots in the SLE cohort), primary anti-phospholipid syndrome (PAPS), 
spondyloarthropathy (SpA), psoriatic arthritis (PsA), and systemic sclerosis (SSc) against SNEC were assessed by ELISA. Using receiver operating characteristic 
(ROC) analysis, the cut-off for positive values was calculated at 246 mean optical density (dashed red line). Frequencies of SNEC positivity are displayed above the 
respective cohort in percent (%). (B) The overall test performance of the SNEC ELISA (left), radioimmunoassay (RIA) dsDNA Farr assay (center), and anti-dsDNA-
NcX-ELISA (right) was evaluated employing ROC analysis. The respective diagnostic parameters (specificity, sensitivity, negative predictive value, positive predictive 
value, and diagnostic odds ratio) were calculated and are displayed below. (c) Organ involvement was analyzed by comparison of odds ratios for SNEC ELISA, 
anti-dsDNA RIA, anti-dsDNA-NcX ELISA, and anti-nuclear antigen on HEp-2 titers. The depicted odd ratios are within the 95% confidence interval.
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SLE serology it does not detect low affinity AAb. Since positive 
test results correlate with disease severity, it is suitable for moni-
toring of SLE disease course and lupus nephritis in individual 
patients (39). Another routine diagnostic assay, the Crithidia 
luciliae immunofluorescence test, turned out to not be a reliable 
screening tool in unselected patients with rheumatic symptoms, 
although it has diagnostic value for a limited number of key SLE 
manifestations such as proteinuria (40). In comparison to these, 
SNEC ELISA appears suitable for broad, quick and cost-efficient 
screening of populations with presumptive diagnosis of SLE. It 
specifically discriminates patients with SLE from those with other 
rheumatic diseases such as RA, SpA, PsA, SSc, or PAPS.
TaBle 3 | Frequencies of organ affection by autoantibody test and statistics from contingency tables.
n Frequency (%) snec elisa anti-dsDna ria anti-dsDna ncX
χ2 p χ2 p χ2 p
Arthritis Yes 95 62.1 0.03 0.853 0.15 0.697 2.58 0.108
No 58
Rash Yes 92 60.1 0.02 0.893 0.06 0.805 0.10 0.751
No 61
Renal Yes 62 40.5 0.37 0.545 2.18 0.140 0.70 0.401
No 91
Cardiovascular Yes 43 28.1 0.03 0.859 5.64 0.018 1.78 0.182
No 110
Leukopenia Yes 47 30.7 2.82 0.093 0.15 0.700 0.49 0.482
No 106
Cerebral Yes 38 24.8 6.87 0.009 0.19 0.663 0.00 0.980
No 115
Lung Yes 35 22.9 0.63 0.427 0.15 0.696 2.18 0.139
No 118
Thyroid Yes 31 20.3 0.19 0.666 2.52 0.113 4.92 0.027
No 122
Photosensitivity Yes 24 15.7 8.81 0.003 5.58 0.018 5.92 0.015
No 129
Vasculitis Yes 21 13.7 0.00 0.967 0.00 0.995 0.80 0.372
No 132
Liver Yes 13 8.5 3.12 0.077 0.39 0.535 3.85 0.050
No 140
Hemolysis Yes 17 11.1 0.00 0.964 0.64 0.423 1.53 0.216
No 136
MOF Yes 2 1.3 0.83 0.361 0.12 0.734 1.57 0.210
No 150
Anti-dsDNA, anti-double stranded deoxyribonucleic acid antibodies; NcX, nucleosomes; RIA, radio immunosorbent assay; SNEC, secondary NEcrotic cells; MOF, multiple organ 
failure.
The bold fond indicates p value ≤ 0.05.
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Anti-dsDNA AAb do not only recognize helical B-DNA 
but also bent DNA present in the large intergenic regions of 
chromatin (41, 42). The anti-dsDNA-NcX-ELISA utilizes dsDNA 
complexed with nucleosomes for the detection of anti-nuclear 
antibodies. However, considering our findings, this substrate 
might not completely reflect the full arsenal of (apoptosis-
associated) autoantigens recognized by SLE AAb. We confirmed 
the presence in SNEC of apoptosis-associated chromatin modifi-
cations reportedly associated with SLE (43) such as H3-K27me3, 
H2A/H4-AcK8,12,16, and H2B-AcK12. Consistently, standard 
serological variables such as ENA and ANA reactivity signifi-
cantly correlated with SNEC positivity. Likewise, nucleosomes 
and dsDNA, representing classical autoantigenic targets for 
SLE-specific AAb, were accessible. We observed that HMGB1 is 
present in SNEC extending the repertoire of apoptosis-related 
autoantigens. HMBG1 reportedly to co-precipitates with anti-
histone and anti-dsDNA antibodies and appears complexed 
with free nucleosomes in the circulation of patients with SLE 
(10). HMGB1-containing nucleosomes from apoptotic cells 
induce anti-dsDNA and anti-histone IgG-mediated responses in 
a toll-like receptor 2-dependent manner (44). The accessibility 
of HMGB1-containing nucleosomes in our assay highlights the 
importance of SNEC material in the pathogenesis of SLE (45).
Deposition of circulating and in situ formed ICs is known to 
be a critical factor triggering inflammation and tissue damage 
in SLE. They consist of assorted intracellular material exposing 
various modified epitopes to AAb (46, 47). Evidence that cellular 
debris accumulates as extracellular material in tissues exclusively 
in SLE patients goes back to the 50 s (48–50) and was revisited 
recently (51). The uptake of these ICs into phagocytes has been 
shown to bepro-inflammatory and mediated by FcγR (12, 18). We 
observed a significant correlation between the presence of anti-
SNEC AAb and the uptake of SNEC into CD16POS granulocytes. 
Some of the SLE sera employed did not facilitate phagocytosis of 
SNEC, although anti-SNEC IgG was measured by SNEC ELISA. 
Since the employed phagocytosis assay is a complex biological 
system, it might be less sensitive than SNEC ELISA. Thus, low 
amounts of AAb which can already be detected by SNEC ELISA, 
do not facilitate the uptake of measurable amounts of SNEC by 
neutrophils. Adsorption of anti-SNEC AAb from serum resulted 
in substantial reduction of SNEC uptake into granulocytes. Even 
a mild reduction of anti-SNEC autoantibody levels resulted in 
strongly diminished phagocytosis. Thus, we suggest that SNEC 
ELISA enables the detection of pathogenic AAb in SLE sera.
We hypothesize that the AAb measured by SNEC ELISA induce 
the pathomechanism depicted in Figure 5. In healthy individuals 
FigUre 3 | Anti-secondary NEcrotic cell (SNEC) IgG correlates with serological disease variables but not with the disease activity. The correlation of SNEC ELISA 
levels with serological and clinical variables was evaluated by Bravais-Pearson correlation coefficients and corrected after Bonferroni. SNEC positivity was compared 
to (a) anti-nuclear antigen on HEp-2 cell titers, (B) extractable nuclear antigen positivity (Nucleosomes, Histones, Ro52), (c) Complement C3 levels (cut off C3 levels 
at 90 mg/ml indicated as blue dotted line), (D) European Consensus Lupus Activity Measurement Manifestation Score and others (see also Tables 1, 2 and S1, S2 in 
Supplementary Material). The SNEC ELISA cut-off at 246 mean optical density is depicted as a red dotted line.
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(NHD), apoptotic cells are swiftly engulfed by phagocytes without 
the induction of inflammatory responses, a process referred to as 
efferocytosis (Figure 5) (15). The recognition of phosphatidylser-
ine on the outer surface of the dead or dying cell is a key step in this 
process. It engages several different proteins and lipids including 
αVβ3 integrin, TAM receptors (Tryo3, Axl, Mer), milk fat globule-
EGF factor 8 protein (MFG-E8), growth arrest-specific protein 6 
(Gas6), protein S and phosphatidylserine (15). Upon recognition, 
FigUre 4 | Continued
FigUre 5 | Inflammation in SLE is driven by FcγR-mediated uptake into phagocytes of secondary NEcrotic cell (SNEC) opsonized by autoantibodies (AAb).  
In healthy individuals (NHD), apoptotic cells are cleared rapidly and silently by professional phagocytes involving a plethora receptors and bridging molecules such as 
αVβ3 integrin, Tryo3–Axl–Mer (TAM), milk fat globule-EGF factor 8 protein (MFG-E8), growth arrest-specific protein 6 (Gas6), and Proteins S. This marked redundancy 
avoids disintegration of apoptotic cells and the generation of SNEC. In patients with systemic lupus erythematosus (SLE), the concurrence of AAb and SNEC results 
in the opsonization and Fcγ Receptor (FcγR)-mediated uptake of SNEC into phagocytes, especially neutrophils. This perpetuates inflammatory responses and 
causes tissue damage. Lupus erythematosus (LE) cell.
FigUre 4 | Secondary NEcrotic cell (SNEC) positivity correlates with uptake of SNEC into blood-borne neutrophils. (a) Correlation of SNEC uptake by neutrophils 
assessed by flow cytometry with anti-SNEC IgG. Values are displayed as ranks. Spearman’s rank correlation coefficient was calculated using the values of patients 
with SLE. (B) Representative microphotographs of z-stack series showing that PI-stained SNEC (red) was taken up by neutrophils with a segmented nucleus 
(CD15POS; displayed in green; Hoechst 33342POS; displayed in blue). White arrows indicate SNEC taken up by neutrophils. SNEC phagocytosed by a CD15NEG 
mononuclear phagocyte is indicated by a red arrow. (c) Uptake of PI-stained SNEC by CD16POS HLA-DRNEG granulocytes in whole blood assessed by flow 
cytometry in the presence (+SNEC, non-adsorbed) or absence (+SNEC, adsorbed) of anti-SNEC autoantibodies. CD16POS HLA-DRNEG granulocytes in whole 
blood without addition of SNEC served as negative control (−SNEC). Shown is the uptake of SNEC in the presence of a representative adsorbed and non-adsorbed 
SLE serum. (D) Percentage of SNEC uptake into CD16POSHLA-DRNEG granulocytes in the presence of 10 anti-SNEC antibody adsorbed SLE sera relative to the 
corresponding non-adsorbed sera. (e) Percentage of residual anti-SNEC IgG in adsorbed relative to the corresponding non-adsorbed sera assessed by SNEC ELISA.
11
Biermann et al. Anti-SNEC-IgG—Cherrypicking SLE-Specific AAb
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 989
phagocytes release immunomodulatory factors including TGFβ 
suppressing the inflammatory responses by surrounding cells. This 
enables the silent clearance of billions of dead and dying cells daily. 
In systemic lupus erythematosus (SLE), AAb recognize nuclear 
material derived from apoptotic cells that had escaped canoni-
cal clearance (SNEC) (Figure 5). It is known that the formation 
of ICs composed of SNEC and AAb activates complement and 
induces inflammation via uptake of these opsonized complexes 
(12, 13, 52). Blood-borne phagocytes, especially Neutrophils, 
taking up opsonized SNEC have formerly been described as LE 
cells. In contrast to the silent effero cytosis, Fc gamma receptor 
(FcγR)-dependent uptake of nucleic acid containing SNEC favors 
the release of pro-inflammatory mediators (15, 53). It was dem-
onstrated that FcγRIIA-mediated contact with soluble ICs results 
in formation of NETs in vivo (54). Although we did not observe 
release of NETs in response to anti-SNEC antibody-mediated IC 
uptake employing life cell imaging phagocytosis experiments, it 
poses an interesting topic for future investigations.
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Secondary NEcrotic cell-autoantibody complexes carry DNA, 
which is considered a danger signal by the immune system con-
fusing them with opsonized virus particles (virus-mimetic), 
and consequently triggers DNA sensing proinflammatory path-
ways. The latter include TLR-9, cyclic GMP-AMP synthase, 
DNA-dependent activator of IFN-regulatory factors, absent in 
melanoma 2, STING, gamma-interferon inducible protein-16, 
nucleotide-binding domain leucine-rich repeat containing pro-
tein family pyrin domain containing 3, DEAD/H-box helicase 41, 
and meiotic recombination 11 protein [summarized in Ref. (55)]. 
These molecules stimulate type I IFN expression, referred to 
as the IFN signature, shared by most patients with SLE, which 
correlates with the clinical appearance and severity of SLE (56).
This study gives insight into the mechanism of SLE etiopatho-
genesis with respect to autoantibody pathogenicity in terms of 
FcγR-mediated phagocytosis and provides the basis for improved 
serological screening of SLE. However, limitations of the study 
have to be considered. First, SLE patients were under treatment 
and thus often showed low disease activity. The lack of a full range 
ECLAM distribution might create a bias that partially explains 
the absence of an association of anti-nuclear antibody tests 
with disease activity scores. Moreover, it was demonstrated that 
anti-nucleosome antibodies present in serologically active but 
clinically quiescent patients predicted future flares (57). SNEC 
ELISA might detect AAb which did not result in increased dis-
ease activity yet. In fact, that the test performance is not affected 
by the patients’ clinical status renders SNEC ELISA a robust 
screening test for patients with suspected SLE. Second, our study 
analyzed patients from a single center. Investigations of several 
patient groups from different study centers (multicenter study) 
are required to confirm applicability to different ethnicities. The 
investigations of specific intracellular DNA-sensors and related 
signaling pathways in neutrophils will provide further insights in 
the pathogenesis of SLE with potential therapeutic applications. 
In conclusion, in this study, we confirm that SNEC uptake is 
intimately linked with the pathogenesis of the disease. We also 
demonstrate that the detection of anti-SNEC antibodies is a 
powerful tool supporting the diagnosis of SLE and the exclusion 
of other autoimmune connective tissue diseases.
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